Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1999 1
2002 12
2003 10
2004 15
2005 16
2006 12
2007 18
2008 16
2009 20
2010 15
2011 16
2012 22
2013 18
2014 14
2015 22
2016 13
2017 10
2018 14
2019 30
2020 23
2021 26
2022 28
2023 21
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Results by year

Filters applied: . Clear all
Page 1
2022 update of the drug resistance mutations in HIV-1.
Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Günthard HF, Paredes R, Shafer RW, Richman DD. Wensing AM, et al. Among authors: calvez v. Top Antivir Med. 2022 Oct;30(4):559-574. Top Antivir Med. 2022. PMID: 36375130 Free PMC article.
SARS-CoV-2 variant-dependent inflammasome activation.
Teyssou E, Marot S, Gothland A, Malet I, Zafilaza K, Leducq V, Cocherie T, Todesco E, Soulié C, Marcelin AG, Calvez V. Teyssou E, et al. Among authors: calvez v. J Infect. 2023 Jul;87(1):62-63. doi: 10.1016/j.jinf.2023.04.005. Epub 2023 Apr 13. J Infect. 2023. PMID: 37060923 Free PMC article. No abstract available.
Recommendations on data sharing in HIV drug resistance research.
Inzaule SC, Siedner MJ, Little SJ, Avila-Rios S, Ayitewala A, Bosch RJ, Calvez V, Ceccherini-Silberstein F, Charpentier C, Descamps D, Eshleman SH, Fokam J, Frenkel LM, Gupta RK, Ioannidis JPA, Kaleebu P, Kantor R, Kassaye SG, Kosakovsky Pond SL, Kouamou V, Kouyos RD, Kuritzkes DR, Lessells R, Marcelin AG, Mbuagbaw L, Minalga B, Ndembi N, Neher RA, Paredes R, Pillay D, Raizes EG, Rhee SY, Richman DD, Ruxrungtham K, Sabeti PC, Schapiro JM, Sirivichayakul S, Steegen K, Sugiura W, van Zyl GU, Vandamme AM, Wensing AMJ, Wertheim JO, Gunthard HF, Jordan MR, Shafer RW. Inzaule SC, et al. Among authors: calvez v. PLoS Med. 2023 Sep 22;20(9):e1004293. doi: 10.1371/journal.pmed.1004293. eCollection 2023 Sep. PLoS Med. 2023. PMID: 37738247 Free PMC article.
Reply to Ambrosioni et al.
Günthard HF, Calvez V, Paredes R, Pillay D, Shafer RW, Wensing AM, Jacobsen DM, Richman DD. Günthard HF, et al. Among authors: calvez v. Clin Infect Dis. 2019 May 17;68(11):1977-1978. doi: 10.1093/cid/ciy1022. Clin Infect Dis. 2019. PMID: 30520997 No abstract available.
When and how to use maraviroc in HIV-infected patients.
Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, di Perri G, Pillay D, Rockstroh J, Geretti AM. Soriano V, et al. Among authors: calvez v. AIDS. 2009 Nov 27;23(18):2377-85. doi: 10.1097/QAD.0b013e328332d32d. AIDS. 2009. PMID: 19834318 Review. No abstract available.
The future of integrase inhibitors of HIV-1.
Malet I, Calvez V, Marcelin AG. Malet I, et al. Among authors: calvez v. Curr Opin Virol. 2012 Oct;2(5):580-7. doi: 10.1016/j.coviro.2012.08.005. Epub 2012 Sep 12. Curr Opin Virol. 2012. PMID: 22980926 Review.
Resistance to novel drug classes.
Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V. Marcelin AG, et al. Among authors: calvez v. Curr Opin HIV AIDS. 2009 Nov;4(6):531-7. doi: 10.1097/COH.0b013e328331d4b1. Curr Opin HIV AIDS. 2009. PMID: 20048722 Review.
363 results